 | Drug Safety Update MHRA September 2019 PDF.pdf (291KB) | 23/09/2019 | Download |
| | | |
| Drug Safety Update MHRA July 2019 PDF.pdf (398KB) | 18/07/2019 | Download |
| | Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease. Tocilizumab (RoActemra): rare risk... | |
| Drug Safety Update MHRA June 2019 PDF.pdf (274KB) | 20/06/2019 | Download |
| | Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome . GLP-1 receptor agonists: reports of diabetic ketoacidosis when... | |
| Drug Safety Update MHRA May 2019 .pdf (512KB) | 22/05/2019 | Download |
| | Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions, Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism... | |
| Drug Safety Update MHRA April 2019 PDF final.pdf (304KB) | 25/04/2019 | Download |
| | Yellow, fever, stamaril, valproate, belimumab, benlysta, lyrica, pregabalin, gabapentin, elvitegravir | |
| Drug Safety Update MHRA March 2019 PDF-final.pdf (388KB) | 25/03/2019 | Download |
| | Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. Onivyde (irinotecan, liposomal... | |
| Drug safety Update MHRA February 2019.pdf (219KB) | 18/02/2019 | Download |
| | Carbimazole: increased risk of congenital malformations; strengthened advice on contraception. Carbimazole: increased risk of Pancreatitis. SGLT2 inhibitors: reports of Fournier's gangrene. | |
| Drug Safety Update MHRA January 2019.pdf (366KB) | 11/01/2019 | Download |
| | Tapentadol: risk of seizures & reports of serotonin syndrome when co-administered with other medicines.Ipilimumab: reports of cytomegalovirus GU infection or reactivation. | |
| Drug Safety Update MHRA December 2018.pdf (262KB) | 19/12/2018 | Download |
| | Oral lidocaine-containing products for infant teething. Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients. Direct-acting... | |
| Drug Safety Update MHRA November 2018.pdf (348KB) | 14/11/2018 | Download |
| | Latest advice for medicines users | |
| Drug safety Update October 2018 PDF.pdf (243KB) | 11/10/2018 | Download |
| | Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in patients in a clinical trial.Ritonavir-containing products:... | |
| MHRA DSU September 2018 PDF.pdf (267KB) | 25/09/2018 | Download |
| | Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers. Xofigo▼ (radium-223-dichloride): new restrictions on use due to increased risk of fracture and... | |
